| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.77 M CAD | -6.99 M CAD | -7.28 M CAD | -15.58 M CAD | -9.79 M CAD | -7.37 M CAD |
| Depreciation & Amortization | 212839 CAD | 219600 CAD | 202249 CAD | 185657 CAD | 120866 CAD | 112429 CAD |
| Stock-Based Compensation | 119307 CAD | 137714 CAD | 278155 CAD | 697894 CAD | 610193 CAD | 994401 CAD |
| Capital Expenditures | — | 9293 CAD | 160014 CAD | 39108 CAD | 1725 CAD | 42573 CAD |
| Cash Flow from Investing | — | -9293 CAD | -661804 CAD | -672999 CAD | -1725 CAD | 3.79 M CAD |
| Cash Flow from Financing | 12.27 M CAD | 4.65 M CAD | 10.68 M CAD | 15.07 M CAD | 10.85 M CAD | -30993 CAD |
| Dividends Paid | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — |
| Free Cash Flow | — | -7.00 M CAD | -7.44 M CAD | -15.62 M CAD | -9.79 M CAD | -7.42 M CAD |
InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada. The company focuses on researching and developing cannabinoid-based pharmaceutical products targeting diseases with high unmet medical needs, particularly in dermatology, ophthalmology, and neurodegenerative disorders. Its lead product candidate, INM-755, is a cannabinol-based topical cream for epidermolysis bullosa, having completed Phase 2 clinical trials. Additional pipeline assets include INM-089, a small molecule selective dual CB1/CB2 agonist for dry age-related macular degeneration, and INM-901 for Alzheimer’s disease, demonstrating preclinical neuroprotective and anti-neuroinflammatory effects. InMed Pharmaceuticals Inc. also develops IntegraSyn, a proprietary biosynthesis-based manufacturing system for pharmaceutical-grade cannabinoids. Previously operating a commercial segment through subsidiary BayMedica producing rare cannabinoids for the health and wellness industry, the company is now concentrating exclusively on advancing its pharmaceutical pipeline toward IND filings and clinical trials. Operating in the healthcare sector, specifically drug manufacturers specializing in novel cannabinoid therapies, InMed Pharmaceuticals Inc. contributes to innovative treatments leveraging cannabinoid science.